QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, July 9, 2008, 28(28):7113-7120; doi:10.1523/JNEUROSCI.3952-07.2008

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Gerfen, C. R. Articles by Worley, P. Search for Related Content PubMed PubMed Citation Articles by Gerfen, C. R. Articles by Worley, P.

 Previous Article  |  Next Article 

Neurobiology of Disease
Differences between Dorsal and Ventral Striatum in Drd1a Dopamine Receptor Coupling of Dopamine- and cAMP-Regulated Phosphoprotein-32 to Activation of Extracellular Signal-Regulated Kinase

Charles R. Gerfen,¹ Ronald Paletzki,¹ and Paul Worley²

¹Laboratory of Systems Neuroscience, National Institute of Mental Health, Bethesda, Maryland 20892, and ²Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Correspondence should be addressed to Charles R. Gerfen, Building 111, National Institutes of Health Animal Center, Dickerson, MD 20842. Email: gerfenc{at}mail.nih.gov

Dopamine receptor signaling exhibits prominent plasticity that is important for the pathogenesis of both addictive and movement disorders. Psychoactive stimulants that activate the dopamine D₁ receptor (Drd1a) induce the rapid phosphorylation and activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in neurons of the nucleus accumbens and ventral striatum. This response is known to be dependent on the phosphatase inhibitor dopamine- and cAMP-regulated phosphoprotein-32 (DARPP-32) and appears critical for the sensitization of Drd1a responses that contributes to addiction. Loss of dopamine input to the striatum, as in models of Parkinson's disease (PD), also results in a sensitization of responses to dopamine agonists that is manifest by increased activation of ERK1/2 in the dorsal striatum. Here, we test whether DARPP-32 is required for sensitization of Drd1a responses in a PD model. In the normal dorsal striatum, there is minimal Drd1a-mediated activation of ERK1/2; however, in the PD model there is robust Drd1a-mediated activation of ERK1/2. In both wild-type and DARPP-32 knock-out mice, Drd1a robustly induces pERK1/2 throughout the dopamine-depleted striatum. These findings indicate that Drd1a sensitization relevant for PD occurs by a novel mechanism that does not require DARPP-32.

Key words: amphetamine; basal ganglia; D₁; dopamine; dopamine receptor; drug abuse; Parkinson's disease; striatum

---

Received March 23, 2007; revised Feb. 27, 2008; accepted May 20, 2008.

Correspondence should be addressed to Charles R. Gerfen, Building 111, National Institutes of Health Animal Center, Dickerson, MD 20842. Email: gerfenc{at}mail.nih.gov

Related articles in J. Neurosci.:

A Potential Neuroanatomical Dissociation of DARPP-32 in Striatal ERK Signaling

Kristin B. Dupre
J. Neurosci. 2008 28: 10783-10785. [Full Text]  

This article has been cited by other articles:

				J. R. Crittenden, I. Cantuti-Castelvetri, E. Saka, C. E. Keller-McGandy, L. F. Hernandez, L. R. Kett, A. B. Young, D. G. Standaert, and A. M. Graybiel Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy PNAS, February 24, 2009; 106(8): 2892 - 2896. [Abstract] [Full Text] [PDF]

				K. B. Dupre A Potential Neuroanatomical Dissociation of DARPP-32 in Striatal ERK Signaling J. Neurosci., October 22, 2008; 28(43): 10783 - 10785. [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help